Bahl & Gaynor’s Meridian Bioscience Inc VIVO Stock Holding History

Bahl & Gaynor’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,300	Closed	-$218K	–	397
2016 Q3	$218K	Sell	11,300 -100	-0.9%	-$1.96K	﹤0.01%	379
2016 Q2	$222K	Hold	11,400	–	–	﹤0.01%	385
2016 Q1	$235K	Hold	11,400	–	–	﹤0.01%	386
2015 Q4	$234K	Hold	11,400	–	–	﹤0.01%	395
2015 Q3	$195K	Sell	11,400 -4,900	-30%	-$89.6K	﹤0.01%	418
2015 Q2	$304K	Hold	16,300	–	–	﹤0.01%	387
2015 Q1	$311K	Sell	16,300 -5,630	-26%	-$104K	﹤0.01%	372
2014 Q4	$361K	Sell	21,930 -12,560	-36%	-$215K	0.01%	337
2014 Q3	$610K	Sell	34,490 -10,678	-24%	-$210K	0.01%	262
2014 Q2	$932K	Sell	45,168 -37,109	-45%	-$763K	0.01%	217
2014 Q1	$1.79M	Sell	82,277 -2,055	-2%	-$47.1K	0.03%	175
2013 Q4	$2.24M	Sell	84,332 -4,285	-5%	-$105K	0.04%	162
2013 Q3	$2.09M	Sell	88,617 -2,590	-3%	-$60.5K	0.04%	160
2013 Q2	$1.96M	Buy	+91,207	New	+$1.97M	0.04%	156

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Bahl & Gaynor's VIVO Position: Q4 2016 in Review

Bahl & Gaynor sold out of Meridian Bioscience Inc (VIVO) in Q4 2016, closing a stake of 11,300 shares — an estimated $218K sold.

Bahl & Gaynor first reported a position in VIVO in Q2 2013 and held it in 14 quarters. The position peaked at $2.24M in Q4 2013. 180 funds tracked by Wall St. Rank hold VIVO as of Q4 2016.

Bahl & Gaynor reported no remaining Meridian Bioscience Inc position as of Q4 2016 after selling out during the quarter.
Bahl & Gaynor sold 11,300 Meridian Bioscience Inc shares in Q4 2016, an estimated $218K.
Bahl & Gaynor first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 14 quarters.
Bahl & Gaynor's Meridian Bioscience Inc position peaked at $2.24M in Q4 2013.
180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2016.

Based on Bahl & Gaynor's 13F filing for Q4 2016, filed 14 Feb 2017.